Increase IGF-1 levels
Improve weight loss
Increase in lean muscle mass
CJC-1295, also known as DAC:GRF or modified GRF 1-29 with DAC, is a synthetic peptide analogous to GHRH.
It comprises the initial 29 amino acids from the 44 amino acid structure of the GHRH, which is the smallest functional GHRH sequence that effectively stimulates the GH secretion from the anterior pituitary gland.
In addition, the CJC-1295 peptide incorporates a structure of GRF 1-29 that has been altered at four positions to enhance its stability against hydrolysis and oxidation, ultimately prolonging the half-life from 10 minutes to 30 minutes when compared to unmodified GRF 1-29.
For example, a notable change is replacing L-alanine with D-alanine at the second position, which increases resistance to the enzyme dipeptidyl peptidase-4 (DPP-4), a key factor in deactivating peptides.
Further, CJC-1295 can be augmented with a drug affinity complex (DAC), enhancing its pharmacokinetic properties. The DAC, attached to the N-terminus of the peptide, significantly extends the half-life of CJC-1295 to about eight days by increasing its binding affinity to plasma proteins.
CJC-1295 was developed by ConjuChem Biotechnologies, a Canadian company, as a potential therapeutic agent for treating lipodystrophy in HIV/AIDS patients.
Individuals with lipodystrophy experience irregular distribution of body fat, characterized by reduced fat in areas like the face and limbs, coupled with an accumulation of fat in the abdominal region and around internal organs (visceral fat).
This condition is commonly seen as a side effect of antiviral treatments in HIV/AIDS patients, and elevating GH levels has a potent fat-burning and muscle-sparing effect.
CJC-1295 works by activating the GHRH receptors in the anterior pituitary gland and stimulating the release of GH.
Trials report that the peptide can lead to a 4-fold increase in mean 24-hour GH levels and up to a 10-fold increase in mean weekly levels.
Healthy young and middle-aged participants received a single subcutaneous dose of CJC-1295, with doses varying between 30 mcg/kg and 250 mcg/kg of body weight.
The results demonstrated that the peptide begins working immediately following administration.
The researchers reported an increase in total GH levels while maintaining GH pulsatility, with peak levels staying within physiological norms. A dose of 60 mcg/kg led to an approximate 150% rise in 24-hour mean GH levels.
Moreover, a single 250 mcg/kg dose resulted in over a 300% increase in 24-hour mean GH levels. Weekly GH levels also increased dose-dependently between 2- and 10-fold.
IGF-1 (insulin-like growth factor-1), which is the main anabolic mediator of GH, also increased significantly 1.5- to 3-fold for 9–11 days following a single administration.
When administered biweekly at a dose of 60 mcg/kg (twice in 14 days), this regimen sustained elevated mean GH levels by the 28th day.
Further research showed that a single injection of CJC-1295 effectively maintained raised GH levels even a week after administration in male subjects aged 20-40 years.
This study reported that 12-hour mean GH levels, measured seven days post-injection, were 46% higher than the baseline levels before treatment.
Unfortunately, the available clinical trials with a duration of up to 14 days were insufficient to report the timeline of effects for CJC-1295. Therefore, longer administration is recommended.
In our clinic, the administration of CJC-1295 is meticulously overseen by seasoned medical professionals.
They adhere closely to strict safety protocols, ensuring not only enhanced treatment efficacy but also comprehensive monitoring and management of any potential side effects that may arise.
CJC-1295 was primarily developed as a peptide for its fat-burning effects, especially in subjects with visceral fat and abnormal fat distribution.
As mentioned, long-term clinical trials are lacking, and shorter studies lasting less than a month do not report any specific benefits other than a significant increase in serum Gh and IGF-1 levels.
Therefore, we have selected high-quality preclinical trials that have employed CJC-1295 in models of growth hormone deficiency (GHD).
GHD is a well-known cause of stunted growth, increased visceral fat, abdominal obesity, and lean mass loss.
When applied to a model of GHD, CJC-1295 led to the following benefits:
Short-term therapy with CJC-1295 can lead to mild to moderate side effects and complaints, such as:
CJC-1295 safety has not been tested in the long term, as the only trial that lasted longer than a few weeks was conducted in HIV/AIDS subjects treated for lipodystrophy.
Yet, this 12-week trial was never published, as it was halted due to the occurrence of a fatal myocardial infarction in one of the subjects. Ultimately, the occurrence was deemed to be likely unrelated to the peptide.
While there may be no direct link between CJC-1295 and cardiovascular problems, the peptide can lead to a significant increase in GH and IGF-1 levels, which is a known risk factor for faster cancer progression.
Thus, CJC-1295 is contraindicated in individuals with active tumors or a history of malignancies.
Due to its extended half-life, CJC-1295 requires only once or twice weekly administration, with research indicating a typical weekly dosage of around 60 mcg/kg.
It is often recommended to inject the peptide in the evening, aligning with the body’s natural rhythm of GH production.
CJC-1295 is not effective when taken orally and is commonly administered through subcutaneous injections.
The peptide is generally available in a lyophilized powder form, which must be mixed with a solvent before use. In its dry form, it can be stored for long periods in a cool, dark, and dry environment.
Bacteriostatic water, which includes 0.9% benzyl alcohol as a preservative, is usually the best choice for a solvent as it can extend the shelf-life of the peptide for up to 28 days when kept refrigerated at temperatures between 36 to 46°F.
When administering reconstituted CJC-1295, it should be injected subcutaneously at appropriate sites, such as around 2 inches from the belly button, the outer area of the upper arms, or the front section of the thighs. It’s important to alternate the injection sites with each dose to avoid scarring.
Ensure you have sterile needles for subcutaneous injections, syringes, alcohol wipes, and a container for disposing of sharps before proceeding with the injection. The steps for injecting CJC-1295 are as follows:
CJC-1295 has an extended half-life of about 8 days. Moreover, its effects have been reported to continue for over two weeks following the last administration. Considering also the fact that most peptides remain in the body for 4-5 half-lives, CJC-1295 may stay in your system for over a month following a single injection and may be detected in blood or urine samples.
CJC-1295 is not associated with the risk of either psychological or physical dependence, and discontinuing its use abruptly does not lead to withdrawal symptoms. Additionally, it does not inhibit the activity of the pituitary gland, ensuring that GH and IGF-1 levels revert to their baseline levels once the treatment with CJC-1295 is ceased.
CJC-1295 activates the GHRH receptors and does not influence other pituitary hormones except for GH. The available studies do not report any effects on other hormones either, such as insulin or testosterone. Yet, it may influence these hormones indirectly by reducing visceral fat and improving metabolic health.
"I struggled with low energy and slow recovery after workouts. Just weeks into using this peptide, I've experienced a remarkable boost in my stamina and muscle growth. It's like I've tapped into a newfound vitality. My workouts are more effective, and I feel rejuvenated. "
"After using CJC-1295, I've seen remarkable changes. My weight loss journey accelerated, and I've gained lean muscle like never before. It's been a game-changer for my fitness goals, making me feel stronger and more energetic. "
Before completion, our doctors will need to evaluate your eligibility for this product. Fill out this form and we will contact you for a free consultation.
Request Appointment
